Control of Metabolic and Cardiovascular Risk in Patients With Schizophrenia and Overweight

CompletedOBSERVATIONAL

Enrollment

430

Participants

Timeline

Start Date

June 30, 2007

Primary Completion Date

June 30, 2009

Study Completion Date

June 30, 2009

Conditions

Schizophrenia

Interventions

OTHER

non-interventional

All Listed Sponsors

lead

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

INDUSTRY

NCT00584519 - Control of Metabolic and Cardiovascular Risk in Patients With Schizophrenia and Overweight | Biotech Hunter | Biotech Hunter